Nuna C. Araújo
University of the Algarve
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Nuna C. Araújo.
Journal of The Chemical Society-perkin Transactions 1 | 2002
Nuna C. Araújo; Pedro M. M. Barroca; Jamie F. Bickley; Amadeu F. Brigas; Maria Lurdes Santos Cristiano; Robert A. W. Johnstone; Rui M. S. Loureiro; Paula C. A. Pena
In contrast to the known thermal, exclusively [3,3], O- to N- rearrangement of allyl groups in phenyltetrazoles (1, Scheme 1), the comparable migration of the allyl group in pseudosaccharyl ethers (3; Scheme 2) has been shown to proceed through both [1,3]- and [3,3]-mechanisms, 4, 5; for the pseudosaccharyl derivative of the natural product myrtenol (6; Scheme 3) only the product 7 of a [1,3]-shift has been observed; crystallographic data and theoretical calculations provide an explanation of this ease of [1,3]-isomerization and the observed selectivity as being due to conformational constraints and electronic factors.
Bioorganic & Medicinal Chemistry Letters | 2009
Nuna C. Araújo; Victoria Barton; M. Jones; Paul A. Stocks; Stephen A. Ward; Jill Davies; Patrick G. Bray; Alison E. Shone; Maria Lurdes Santos Cristiano; Paul M. O'Neill
A novel series of semi-synthetic trioxaquines and synthetic trioxolaquines were prepared, in moderate to good yields. Antimalarial activity was evaluated against both the chloroquine-sensitive 3D7 and resistant K1 strain of Plasmodium falciparum and both series of compounds were shown to be active in the low nanomolar range. For comparison the corresponding 9-amino acridine analogues were also prepared and shown to have low nanomolar activity like their quinoline counterparts.
PLOS ONE | 2017
Carla S. B. Viegas; Rúben M. Costa; Lúcia Santos; Paula A. Videira; Zélia Silva; Nuna C. Araújo; Anjos L. Macedo; A.P. Alves de Matos; Cees Vermeer; Dina C. Simes
Calcification-related chronic inflammatory diseases are multifactorial pathological processes, involving a complex interplay between inflammation and calcification events in a positive feed-back loop driving disease progression. Gla-rich protein (GRP) is a vitamin K dependent protein (VKDP) shown to function as a calcification inhibitor in cardiovascular and articular tissues, and proposed as an anti-inflammatory agent in chondrocytes and synoviocytes, acting as a new crosstalk factor between these two interconnected events in osteoarthritis. However, a possible function of GRP in the immune system has never been studied. Here we focused our investigation in the involvement of GRP in the cell inflammatory response mechanisms, using a combination of freshly isolated human leucocytes and undifferentiated/differentiated THP-1 cell line. Our results demonstrate that VKDPs such as GRP and matrix gla protein (MGP) are synthesized and γ-carboxylated in the majority of human immune system cells either involved in innate or adaptive immune responses. Stimulation of THP-1 monocytes/macrophages with LPS or hydroxyapatite (HA) up-regulated GRP expression, and treatments with GRP or GRP-coated basic calcium phosphate crystals resulted in the down-regulation of mediators of inflammation and inflammatory cytokines, independently of the protein γ-carboxylation status. Moreover, overexpression of GRP in THP-1 cells rescued the inflammation induced by LPS and HA, by down-regulation of the proinflammatory cytokines TNFα, IL-1β and NFkB. Interestingly, GRP was detected at protein and mRNA levels in extracellular vesicles released by macrophages, which may act as vehicles for extracellular trafficking and release. Our data indicate GRP as an endogenous mediator of inflammatory responses acting as an anti-inflammatory agent in monocytes/macrophages. We propose that in a context of chronic inflammation and calcification-related pathologies, GRP might act as a novel molecular mediator linking inflammation and calcification events, with potential therapeutic application.
Parasitology International | 2013
Nuna C. Araújo; Ricardo Afonso; A. Bringela; M L Cancela; Maria Lurdes Santos Cristiano; Ricardo B. Leite
Perkinsus olseni, the causative agent of Perkinsosis, can drastically affect the survival of target marine mollusks, with dramatic economic consequences for aquaculture. P. olseni is a member of the Alveolata group, which also comprises parasites that are highly relevant for medical and veterinary sciences such as Plasmodium falciparum and Toxoplasma. P. olseni shares several unique metabolic pathways with those pathological parasites but is not toxic to humans. In this work, six antimalarially active peroxides, derived from the natural product artemisinin or synthetic trioxolanes, were synthesized and tested on P. olseni proliferation and survival. All peroxides tested revealed an inhibitory effect on P. olseni proliferation at micromolar concentrations. The relevance of the peroxide functionality on toxicity and the effect of Fe(II)-intracellular concentration on activity were also evaluated. Results demonstrated that the peroxide functionality is the toxofore and intracellular iron concentration also proved to be a crucial co-factor on the activation of peroxides in P. olseni. These data points to a mechanism of bioactivation in P. olseni sharing similarities with the one proposed in P. falciparum parasites. Preliminary studies on bioaccumulation were conducted using fluorescent-labeled peroxides. Results show that synthetic trioxolanes tend to accumulate on a vacuole while the labeled artemisinin accumulates in the cytoplasm. Preliminary experiments on differential genes expression associated to Fe(II) transport protein (Nramp) and calcium transport protein (ATP6/SERCA) were also conducted by qPCR. Results point to a fourfold increase in expression of both genes upon exposure to trioxolanes and approximately twofold upon exposure to artemisinin derivatives. Data obtained in this investigation is relevant for better understanding of the biology of Perkinsus and may also be important in the development of new strategies for Perkinsosis prevention and control.
ChemMedChem | 2013
Louise La Pensée; Sunil Sabbani; Raman Sharma; Inder Bhamra; Emma R. Shore; Amy E. Chadwick; Neil G. Berry; James Firman; Nuna C. Araújo; Lília I. L. Cabral; Maria Lurdes Santos Cristiano; Cerys Bateman; Omar Janneh; Adelina Gavrila; Yi Hang Wu; Afthab Hussain; Stephen A. Ward; Paul A. Stocks; Richard Cosstick; Paul M. O'Neill
Greater than the sum of its parts: Artemisinins are currently in phase I-II clinical trials against breast, colorectal and non-small-cell lung cancers. In an attempt to offer increased specificity, a series of hybrid artemisinin-polypyrrole minor groove binder conjugates are described. DNA binding/modelling studies and preliminary biological evaluation give insights into their mechanism of action and the potential of this strategy.
Angewandte Chemie | 2007
Paul A. Stocks; Patrick G. Bray; Victoria Barton; Mohammed Al-Helal; M. Jones; Nuna C. Araújo; Peter Gibbons; Stephen A. Ward; Ruth H. Hughes; Giancarlo A. Biagini; Jill Davies; Richard Amewu; Amy E. Mercer; Gemma L. Ellis; Paul M. O'Neill
Angewandte Chemie | 2004
Paul M. O'Neill; Paul A. Stocks; Matthew D. Pugh; Nuna C. Araújo; Edward E. Korshin; Jamie F. Bickley; Stephen A. Ward; Patrick G. Bray; Erica M. Pasini; Jill Davies; Edite Verissimo; Mario D. Bachi
Journal of Medicinal Chemistry | 2010
Peter Gibbons; Edite Verissimo; Nuna C. Araújo; Victoria Barton; Gemma L. Nixon; Richard Amewu; James Chadwick; Paul A. Stocks; Giancarlo A. Biagini; Abhishek Srivastava; Philip J. Rosenthal; Jiri Gut; Rita C. Guedes; Rui Moreira; Raman Sharma; Neil G. Berry; Maria Lurdes Santos Cristiano; Alison E. Shone; Stephen A. Ward; Paul M. O'Neill
Journal of Molecular Catalysis A-chemical | 2004
Nuna C. Araújo; Amadeu F. Brigas; M. Lurdes S. Cristiano; Luís M.T. Frija; Emanuel Guimarães; Rui M. S. Loureiro
Bioorganic & Medicinal Chemistry Letters | 2006
Paul M. O’Neill; Edite Verissimo; Stephen A. Ward; Jill Davies; Edward E. Korshin; Nuna C. Araújo; Matthew D. Pugh; M. Lurdes S. Cristiano; Paul A. Stocks; Mario D. Bachi